CTOs on the Move

Acucela

www.acucela.com

 
Acucela is a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases impacting millions of individuals worldwide. Acucela currently has the following candidates in development with Otsuka Pharmaceutical: emixustat hydrochloride for GA associated with dry AMD based on Acucela’s proprietary visual cycle modulation; and OPA-6566 for ocular hypertension and glaucoma.
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.acucela.com
  • 1301 2nd Ave # 1900
    Seattle, WA USA 98101
  • Phone: 206.805.8300

Executives

Name Title Contact Details

Similar Companies

Holy Redeemer Health System

Holy Redeemer Health System is committed to our mission to care, comfort and heal, and to providing excellent healthcare services to our community.

Small Bone Innovations (Main) Corp HQ

Small Bone Innovations, LLC (Main) Corp HQ is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Small Bone Innovations, LLC (Main) Corp HQ is based in New York, NY. You can find more information on Small Bone Innovations, LLC (Main) Corp HQ at www.totalsmallbone.com

The Access Group

The Access Group is a Berkeley Heights, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AndHealth

AndHealth is a digital health solution that combines behavioral and clinical care for migraine and autoimmune conditions. Their virtual Center of Excellence delivers a Migraine Reversal Program via mobile app to enable migraine reversal.

Wave Life Sciences

WAVE Life Sciences is utilizing its innovative and proprietary synthetic chemistry drug development platform to design, develop and commercialize stereopure nucleic acid therapeutics that precisely target the underlying cause of rare genetic diseases, delivering exceptional treatment options for patients. Given the unique versatility of its chemistry platform, WAVE`s pipeline will span multiple oligonucleotide modalities including antisense, exon-skipping and single-stranded RNAi.